HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK CBD Limbo Continues – Full List Of ‘Legal’ Products Delayed Until June

Executive Summary

A provisional list of CBD products that can continue to legally be sold in the UK has been issued by the Food Standards Agency. However the list currently only includes products from three suppliers and will not be complete until June 2021, meaning the vast majority of companies face a nervy wait.

You may also be interested in...



UK CBD Industry Vexed As FSA Publishes Searchable Public List – A Year Late

The UK Food Standards Agency has published its much anticipated searchable, online CBD public list. But after a long wait, the list's publication has triggered a wave of anxiety and criticism from CBD firms and experts. 

Authorized CBD Products In UK Could Be Another Two Years Away

While the UK's Food Standards Agency is hopeful it can commence the safety assessment of validated novel food applications for CBD products in the next few months, it could take another two years for products to be fully authorized for sale.

Congressional Research Suggests Additional Layer Of Complexity In FDA’s Cannabinoid Puzzle

Congressional Research Service report says in addition to markets for hemp from fiber, seeds and flowers, “a separate, marketable category exists for the plant’s extracted compounds.” Ingredients from hemp seeds and grains as well as from flowers are alternative protein sources in supplements, foods and beverages and dairy alternatives.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151243

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel